China Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019-2026

August 2019 | 135 pages | ID: CB3BDDB3B316EN
Allied Market Research

Abstracts

The China oncology drugs market was valued at $6,498.2 million in 2018 and is projected to reach $12,688.7 million by 2026, registering a CAGR of 8.7% from 2019 to 2026. Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer according to the data published by WHO. Being the most populous country in the world, cancer rates are significantly rising in China. As per Global Cancer Observatory in 2018, the number of new cancer cases registered each year in China are 4,285,033. Amongst which, lung cancer constitutes 18.1%; colorectum cancer is about 12.2%; stomach cancer is approximately 10.6%; liver cancer constitutes 9.2%; breast cancer comprises of 8.6% and 41.1% other cancers. The population of China accounts for 19.3% of the global population, and the incidence rate of cancer accounts for 22% of global cancer incidence, ranking first in the world. Cancer deaths in China account for about 27% of global cancer deaths. Cancer mortality in China is also higher than the global average of 17%.

Rise in incidence of various cancer conditions, aging population, westernized diet, shift to sedentary lifestyle, and surge in tobacco smoke exposure due to urbanization in China are the key factors that drive the growth of the cancer. This in turn boosts the growth of the China oncology drugs market. Furthermore, rise in cancer awareness and increase in availability of cancer drugs are expected to boost the market growth. However, the use of traditional Chinese medicine (TCM) to cure cancer and high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies are expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.

The China oncology drugs market is segmented based on drug class type and indication. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer, and other cancers.

KEY MARKET BENEFITS

• This report entails a detailed quantitative analysis along with the current China oncology drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market forecast is studied from 2019 to 2026.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Key market segments

By Drug Class Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy Therapy
• Hormonal Therapy

By Indication

• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Skin Cancer
• Ovarian Cancer
• Cervical Cancer
• Kidney Cancer
• Other Cancers

LIST of KEY PLAYERS PRofILED IN THE REPORT

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Shanghai Junshi Biosciences Co., Ltd.
• Beigene
• Jiangsu Hengrui Medicine Co., Ltd

Contents

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
  1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
  1.4.1. Secondary Research
  1.4.2. Primary Research
  1.4.3. Analyst Tools And Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key Findings of The Study
2.2. Cxo Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market Definition And Scope
3.2. Key Findings
  3.2.1. Top Investment Pockets
  3.2.2. Top Winning Strategies, 2018
3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics
  3.4.1. Drivers
    3.4.1.1. Industrial Collaboration
    3.4.1.2. In House Manufacturing
    3.4.1.3. Increase In Incidences of Cancers In The Chinese Population
  3.4.2. Restraint
    3.4.2.1. Preference of Generics And Biosimilars
  3.4.3. Opportunity
    3.4.3.1. Increase In Number of Pipeline Drugs
  3.4.4. Impact Analyses

CHAPTER 4: CHINA ONCOLOGY DRUGS MARKET, BY DRUG CLASS TYPE

4.1. Overview
  4.1.1. Market Size And Forecast
4.2. Chemotherapy
  4.2.1. Key Market Trends, Growth Factors, And Opportunities
  4.2.2. Market Size And Forecast
4.3. Targeted Therapy
  4.3.1. Key Market Trends, Growth Factors, And Opportunities
  4.3.2. Market Size And Forecast
4.4. Immunotherapy (Biologic Therapy)
  4.4.1. Key Market Trends, Growth Factors, And Opportunities
  4.4.2. Market Size And Forecast
4.5. Hormonal Therapy
  4.5.1. Key Market Trends, Growth Factors, And Opportunities
  4.5.2. Market Size And Forecast

CHAPTER 5: CHINA ONCOLOGY DRUGS MARKET, BY INDICATION

5.1. Overview
  5.1.1. Cancer Incidences In China, 2018
  5.1.2. Market Size And Forecast
5.2. Blood Cancer
  5.2.1. Market Size And Forecast
5.3. Breast Cancer
  5.3.1. Market Size And Forecast
5.4. Gastrointestinal And Urinary Cancer
  5.4.1. Market Size And Forecast
  5.4.2. Gb/Cholangiocarcinoma
    5.4.2.1. Market Size And Forecast
  5.4.3. Bladder Cancer
    5.4.3.1. Market Size And Forecast
  5.4.4. Pancreatic Cancer
    5.4.4.1. Market Size And Forecast
5.5. Prostate Cancer
  5.5.1. Market Size And Forecast
5.6. Lung Cancer
  5.6.1. Market Size And Forecast
  5.6.2. Small Cell Lung Cancer (Sclc)
    5.6.2.1. Market Size And Forecast
5.7. Skin Cancer
  5.7.1. Market Size And Forecast
5.8. Ovarian Cancer
  5.8.1. Market Size And Forecast
5.9. Cervical Cancer
  5.9.1. Market Size And Forecast
5.10. Kidney Cancer
  5.10.1. Market Size And Forecast,
5.11. Other Cancers
  5.11.1. Market Size And Forecast

CHAPTER 6: COMPANY PROFILES

6.1. Abbvie Inc.
  6.1.1. Company Overview
  6.1.2. Company Snapshot
  6.1.3. Operating Business Segments
  6.1.4. Product Portfolio
  6.1.5. Business Performance
6.2. Astellas Pharma Inc.
  6.2.1. Company Overview
  6.2.2. Company Snapshot
  6.2.3. Operating Business Segments
  6.2.4. Product Portfolio
  6.2.5. Business Performance
6.3. Astrazeneca Plc
  6.3.1. Company Overview
  6.3.2. Company Snapshot
  6.3.3. Operating Business Segments
  6.3.4. Product Portfolio
  6.3.5. Business Performance
6.4. Bristol-Myers Squibb Company
  6.4.1. Company Overview
  6.4.2. Company Snapshot
  6.4.3. Operating Business Segments
  6.4.4. Product Portfolio
  6.4.5. Business Performance
  6.4.6. Key Strategic Moves And Developments
6.5. Celgene Corporation
  6.5.1. Company Overview
  6.5.2. Company Snapshot
  6.5.3. Operating Business Segments
  6.5.4. Product Portfolio
  6.5.5. Business Performance
  6.5.6. Key Strategic Moves And Developments
6.6. F. Hoffmann-La Roche Ltd.
  6.6.1. Company Overview
  6.6.2. Company Snapshot
  6.6.3. Operating Business Segments
  6.6.4. Product Portfolio
  6.6.5. Business Performance
  6.6.6. Key Strategic Moves And Developments
6.7. Johnson & Johnson
  6.7.1. Company Overview
  6.7.2. Company Snapshot
  6.7.3. Operating Business Segments
  6.7.4. Product Portfolio
  6.7.5. Business Performance
  6.7.6. Key Strategic Moves And Developments
6.8. Shanghai Junshi Biosciences Co., Ltd.
  6.8.1. Company Overview
  6.8.2. Company Snapshot
  6.8.3. Operating Business Segments
  6.8.4. Product Portfolio
  6.8.5. Business Performance
  6.8.6. Key Strategic Moves And Developments
6.9. Beigene
  6.9.1. Company Overview
  6.9.2. Company Snapshot
  6.9.3. Operating Business Segments
  6.9.4. Product Portfolio
  6.9.5. Business Performance
  6.9.6. Key Strategic Moves And Developments
6.10. Jiangsu Hengrui Medicine Co., Ltd.
  6.10.1. Company Overview
  6.10.2. Company Snapshot
  6.10.3. Operating Business Segments
  6.10.4. Product Portfolio
  6.10.5. Key Strategic Moves And Developments

List Of Tables

LIST OF TABLES

Table 01. China Oncology Drugs Market, By Drug Class Type, 2018-2026 ($Million)
Table 02. China Oncology Drugs Market, List of Chemotherapy Drugs
Table 03. China Oncology Drugs Market, List of Targeted Therapy Drugs
Table 04. China Oncology Drugs Market, List of Immunotherapeutic Drugs
Table 05. China Oncology Drugs Market, List of Hormonal Therapy Drugs
Table 06. China Oncology Drugs Market, By Indication, 2018–2026 ($Million)
Table 07. Abbvie: Company Snapshot
Table 08. Abbvie: Operating Segments
Table 09. Abbvie: Product Portfolio
Table 10. Astellas: Company Snapshot
Table 11. Astellas: Products And Services
Table 12. Astellas: Product Portfolio
Table 13. Astrazeneca: Company Snapshot
Table 14. Astrazeneca: Operating Segments
Table 15. Astrazeneca: Product Portfolio
Table 16. Bristol-Myers Squibb: Company Snapshot
Table 17. Bristol-Myers Squibb: Product Portfolio
Table 18. Celgene: Company Snapshot
Table 19. Celgene: Operating Segments
Table 20. Celgene: Product Type Portfolio
Table 21. Roche: Company Snapshot
Table 22. Roche: Operating Segments
Table 23. Roche: Product Type Portfolio
Table 24. J&J: Company Snapshot
Table 25. J&J: Operating Segments
Table 26. J&J: Product Type Portfolio
Table 27. Shanghai Junshi Biosciences Co., Ltd.: Company Snapshot
Table 28. Shanghai Junshi Biosciences Co., Ltd: Operating Segments
Table 29. Shanghai Junshi Biosciences Co., Ltd.: Product Type Portfolio
Table 30. Beigene: Company Snapshot
Table 31. Beigene: Operating Segments
Table 32. Beigene: Product Type Portfolio
Table 33. Jiangsu Hengrui Medicine Co., Ltd: Company Snapshot
Table 34. Jiangsu Hengrui Medicine Co., Ltd: Operating Segments
Table 35. Jiangsu Hengrui Medicine Co., Ltd: Product Type Portfolio

List Of Figures

LIST OF FIGURES

Figure 01. China Cancer Drugs Market Segmentation
Figure 02. Top Investment Pockets
Figure 03. Top Winning Strategies, 2016–2019*
Figure 04. Top Winning Strategies, By Year, 2016–2019*
Figure 05. Top Winning Strategies: Nature And Type, 2016–2019*
Figure 06. Moderate Barganing Power of Buyers
Figure 07. High Barganing Power of Suppliers
Figure 08. Moderate Threat of Substitution
Figure 09. Moderate Threat of New Entrants
Figure 10. High Competitive Rivalry
Figure 11. Number of New Cases In 2018, All Ages (%) Males
Figure 12. Number of New Cases In 2018, All Ages (%) Females
Figure 13. Impact Analyses
Figure 14. Chemotherapy Market, 2018–2026 ($Million)
Figure 15. Targeted Therapy Market, 2018–2026 ($Million)
Figure 16. Immunotherapy Market, 2018–2026 ($Million)
Figure 17. Hormonal Therapy Market, 2018–2026 ($Million)
Figure 18. Number of Cancer Incidences In 2018, China
Figure 19. Cancer Incidences In 2018 & 5 Year Prevalance, China
Figure 20. China Blood Cancer Market, 2018–2026 ($Million)
Figure 21. China Breast Cancer Market, 2018–2026 ($Million)
Figure 22. China Gastrointestinal Cancer Market, 2018–2026 ($Million)
Figure 23. China Gastrointestinal Cancer Market, For Cholangiocarcinoma, 2018–2026 ($Million)
Figure 24. China Bladder Cancer Market, For Bladder Cancer, 2018–2026 ($Million)
Figure 25. China Gastrointestinal Cancer Market, For Pancreatic Cancer, 2018–2026 ($Million)
Figure 26. China Prostate Cancer Market, 2018–2026 ($Million)
Figure 27. China Lung Cancer Market, 2018–2026 ($Million)
Figure 28. China Lung Cancer Market, 2018–2026 ($Million)
Figure 29. China Skin Cancer Market, 2018–2026 ($Million)
Figure 30. China Ovarian Cancer Market, 2018–2026 ($Million)
Figure 31. China Cervical Cancer Market, 2018–2026 ($Million)
Figure 32. China Kidney Cancer Market, 2018–2026 ($Million)
Figure 33. China Other Cancer Market, 2018–2026 ($Million)
Figure 34. Abbvie: Net Sales, 2016–2018 ($Million)
Figure 35. Abbvie: Revenue Share By Segment, 2018 (%)
Figure 36. Abbvie: Revenue Share By Region, 2018 (%)
Figure 37. Astellas: Sales, 2016–2018 ($Million)
Figure 38. Astellas: Sales Share By Products And Services, 2018 (%)
Figure 39. Astellas: Revenue Share By Region, 2018 (%)
Figure 40. Astrazeneca: Revenue, 2016–2018 ($Million)
Figure 41. Astrazeneca: Revenue Share By Region, 2018 (%)
Figure 42. Revenue, 2016–2018 ($Million)
Figure 43. Bristol-Myers Squibb: Sales Share By Products And Services, 2018 (%)
Figure 44. Bristol-Myers Squibb: Revenue Share By Region, 2018 (%)
Figure 45. Celgene: Revenue, 2016–2018 ($Million)
Figure 46. Celgene: Revenue Share By Segment, 2018 (%)
Figure 47. Celgene: Revenue Share By Region, 2018 (%)
Figure 48. Roche: Net Sales, 2016–2018 ($Million)
Figure 49. Roche: Revenue Share By Segment, 2018 (%)
Figure 50. Roche: Revenue Share By Region, 2018 (%)
Figure 51. J&J: Revenue, 2016–2018 ($Million)
Figure 52. J&J: Revenue Share By Segment, 2018 (%)
Figure 53. J&J: Revenue Share By Region, 2018 (%)
Figure 54. Shanghai Junshi Biosciences Co., Ltd.: Revenue, 2016–2018 ($Million)
Figure 55. Beigene: Revenue, 2016–2018 ($Million)
Figure 56. Beigene: Revenue Share By Region, 2018 (%)